TCM
CLLS

Trent Capital Management’s Cellectis CLLS Stock Holding History

Trent Capital Management’s Portfolio CLLS Stock Details CLLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$2K Buy
+105
New +$1.94K ﹤0.01% 79

Other funds holding CLLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Trent Capital Management's CLLS Position: Q4 2016 in Review

Trent Capital Management opened a new position in Cellectis (CLLS) in Q4 2016: 105 shares worth $2K. The stake represents ﹤0.01% of the portfolio and ranks #79 among its holdings.

37 funds tracked by Wall St. Rank hold CLLS as of Q4 2016.

  • Trent Capital Management held 105 shares of Cellectis worth $2K as of Q4 2016.
  • Cellectis was a new Trent Capital Management position in Q4 2016.
  • Cellectis made up ﹤0.01% of Trent Capital Management's portfolio in Q4 2016, its #79 holding.
  • 37 funds tracked by Wall St. Rank held Cellectis as of Q4 2016.

Based on Trent Capital Management's 13F filing for Q4 2016, filed 1 Feb 2017.